A Manchester-based drug discovery company has signed an exclusive worldwide licensing agreement with AstraZeneca worth up to $402m.
After the deal was announced, shares in AIM-listed C4X Discovery Holdings plc jumped by almost 40% to their highest since May.
AstraZeneca will develop and commercialise an oral therapy for the treatment of inflammatory and respiratory diseases with a lead focus on chronic obstructive pulmonary disease (COPD).
